Join us today at 3pm CET / 9am ET for a webcast discussing the U.S. FDA approval of the Company’s chikungunya vaccine ow.ly/coEf50Q6RIz

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment ow.ly/Cm4150QbnGL

🎉🏆Congratulations are in order for our Valneva Scotland colleagues, who picked up the Innovation & Resilience award at Friday’s West Lothian Chamber of Commerce Business Excellence Ceremony! #LifeAtValneva #Innovation #Resilience

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® ow.ly/P20550QeSA8

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 ow.ly/ltjI50QfgYT

Congrats to our partner Instituto Butantan for their submission to the Brazilian health regulatory agency Anvisa. Through the OPEN initiative for joint assessment of medicines with the EMA, Anvisa will evaluate the application to register our chikungunya vaccine candidate in Brazil

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum valneva.com/press-release/…

Valneva Announces Sale of Priority Review Voucher for $103 Million valneva.com/press-release/…

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance valneva.com/press-release/…

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® valneva.com/press-release/…

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences valneva.com/press-release/…

Did you know #MosquitoBorneDiseases affect up to one in 10 people globally? Warming climates extend mosquito seasons, spreading diseases like #chikungunya worldwide. To learn more, check out our article here: bitly.ws/3bZKp #ClimateChange

🏆 Valneva was recognized not once, but TWICE, at Scotland’s Life Sciences Awards 2024. Congratulations to our colleagues in Scotland for the hard work that led to their award wins in the Outstanding Skills Development & Innovation – Pharm Services and Drug Discovery categories!

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook valneva.com/press-release/… ➡️ Find more year-end publications in Valneva’s 2023 Annual Reporting Hub: valneva.com/2023-annual-re…

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. valneva.com/press-release/…

In 2023: ➡️ 100% of the energy contracted for our manufacturing and R&D sites was of renewable origin ➡️ 56% of our workforce was women ➡️ a new sustainability governance model was implemented at Valneva Read more in our 2023 Sustainability Report: ow.ly/n1Km50R0Np1

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com/press-release/…

🏆 We are very pleased to announce that Valneva has won for Best Prophylactic Vaccine at this year’s Vaccine Industry Excellence (VIE) Awards! We're honored to receive this recognition of our chikungunya vaccine. #WVCDC #WVCUSA World Vaccine Congress

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates valneva.com/press-release/… Conference call webcast at 3 p.m. CEST/9 a.m. EDT today: edge.media-server.com/mmc/p/wrc2a7s3

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine ow.ly/G3gh50RCSAY